Exelixis
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Exelixis and other ETFs, options, and stocks.About EXEL
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic.
CEOMichael M. Morrissey
CEOMichael M. Morrissey
Employees1,310
Employees1,310
HeadquartersAlameda, California
HeadquartersAlameda, California
Founded1994
Founded1994
Employees1,310
Employees1,310
EXEL Key Statistics
Market cap9.51B
Market cap9.51B
Price-Earnings ratio21.21
Price-Earnings ratio21.21
Dividend yield—
Dividend yield—
Average volume2.52M
Average volume2.52M
High today$33.68
High today$33.68
Low today$32.70
Low today$32.70
Open price$33.30
Open price$33.30
Volume7.65M
Volume7.65M
52 Week high$36.97
52 Week high$36.97
52 Week low$19.20
52 Week low$19.20
EXEL News
Simply Wall St 2d
The five-year decline in earnings might be taking its toll on Exelixis shareholders as stock falls 4.3% over the past weekPassive investing in index funds can generate returns that roughly match the overall market. But in our experience, buying the right stocks can give your wealth...
Seeking Alpha 5d
Exelixis cut to neutral from buy by BofABofA has downgraded Exelixis () to neutral from buy, commenting that it sees a more balanced risk/reward following the stock’s recent run-up....
TipRanks 5d
Exelixis downgraded to Neutral at BofA following 37% rallyAs previously reported, BofA downgraded Exelixis (EXEL) to Neutral from Buy with a price target of $39, up from $35. The stock price has gained 37% following a...
Analyst ratings
52%
of 23 ratingsBuy
52.2%
Hold
39.1%
Sell
8.7%
More EXEL News
TipRanks 5d
Exelixis downgraded to Neutral from Buy at BofABofA analyst Jason Gerberry downgraded Exelixis (EXEL) to Neutral from Buy with a $39 price target Published first on TheFly – the ultimate source for real-tim...